55/73
  • Pages
  • Editions
01 Cover
02 Welcome Letter / Sections
03 Article & Interview Directory
04 Section 1: Introduction
05 Introduction to US Life Sciences
06 Janssen Pharmaceuticals Interview
07 Investment Climate
08 MPM Capital Interview
09 Signet Healthcare Partners Interview
10 Xontogeny Interview
11 Insights from EisnerAmper
12 The Life Sciences Regulatory Climate
13 Buchanan Ingersoll & Rooney PC Interview
14 PhRMA Interview
15 PBOA Interview
16 Ernst & Young LLP Interview
17 LaVoieHealthScience Interview
18 Section 2: Introducing the Hubs
19 East Coast
20 BioNJ Interview
21 MassBio Interview
22 Pennsylvania Biotechnology Center Interview
23 West Coast
24 Biocom California Interview
25 QB3-Berkeley Interview
26 Section 3: Drug Discovery and Development
27 Therapeutic Fields On Fire
28 Insmed Interview
29 Mammoth Biosciences Interview
30 Innovations Enhancing the Patient Experience
31 Arcturus Therapeutics Interview
32 Karius Interview
33 Expert Insights: Targeted Therapeutics
34 First Wave BioPharma Interview
35 Aphios Corporation Interview
36 Section 4: Contract Manufacturing and Chemicals
37 A Shifting Landscape
38 Syngene International Interview
39 Cambrex Interview
40 Lubrizol Life Science Interview
41 Aenova Group Interview
42 Keeping Up With Demands
43 Cureline Interview
44 Interview: Murli Krishna Pharma
45 PsychoGenics Interview
46 Expert Insights: Innovative Technologies
47 AMPAC Fine Chemicals Interview
48 TCG Lifesciences Interview
49 CordenPharma Interview
50 Quotient Sciences Interview
51 A Post-Pandemic World
52 New Vision Pharmaceuticals Interview
53 Adare Pharma Solutions Interview
54 Ascendia Pharmaceuticals Interview
55 Chemicals Producers and Distributors
56 Brenntag North America Interview
57 BASF Pharma Solutions Interview
58 Section 5: Technology Services
59 Life Sciences Go Digital
60 RxS Interview
61 Insights from Markem-Imaje
62 AiCure Interview
63 WhizAI Interview
64 Section 6: Company Profiles
65 Brenntag Company Profile
66 Adare Pharma Solutions Company Profile
67 Quotient Sciences Company Profile
68 SK pharmteco Company Profile
69 AiCure Company Profile
70 Markem-Imaje Company Profile
71 TCG Lifesciences Company Profile
72 Murli Krishna Pharma Company Profile
73 Credits

Chemicals Producers and Distributors

Chemicals providers play a crucial role equipping their customers with the appropriate materials

and processes to meet a changing landscape

Just as CDMOs are diversifying their capabilities to meet their clients’ ever-complexifying demands, providers of chemicals solutions are working to stay ahead of new market trends based on the desires of pharma companies and their end customers.

As drug molecules both small and large become more difficult to formulate, formulators require new tools to work with. BASF Pharma Solutions works on producing novel excipients like its Kollicoat Smartseal 100 P for efficient taste masking and its Soluplus, the first polymeric solubilizer and matrix forming polymer. This type of innovation is not without its challenges, however. As David Freidinger, vice president of global business management for BASF Pharma Solutions pointed out: “Producing innovative and novel excipients remains challenging and comes with significant business risk. Regulatory agencies historically look at excipients as the sum of the formulation rather than individually, complicating the process. Our hope is that a dedicated excipient registration and qualification process helps overcome risk adversity and enables more innovative investments in the space.”

In addition to stringent regulatory concerns inherent to the therapeutics ecosystem, shifting consumer demands are top-of-mind for business leaders of chemicals companies. Roquette has long offered plant-based ingredients made as by-products from the starch extracted from corn, wheat, potatoes and peas. As one of the largest excipients suppliers in the world, Roquette is the largest producer of ingredients that go into meltables, tablets that melt in the patient’s mouth, according to Paul Smaltz, VP global business unit pharmaceuticals. Smaltz noted that it is his company’s nutraceutical offerings that have been receiving particular attention recently.

Over the past few years, consumers have taken an increased interest to nutraceuticals as people begin to pay more attention to their overall health. “Increasingly, people want to make choices at the pharmacy that impact what they put in their bodies, such as deciding between a plant-based soft gel or an animal derived product,” said Smaltz. “With the pandemic, people are more conscious than ever about what they put in their bodies and how to stay healthy.”

Ultimately, however, chemicals providers and their customers are not concerned simply with what goes into these molecules, but also how they are made. ESG is more crucial than ever, and Lars Schneider, president of Brenntag Specialties Americas, who received an award from the non-profit Water for People in 2021 in addition to being appointed to its leadership council, provides a good example. “Some of the projects at Brenntag include optimizing the supply chain of customers and suppliers with the impact of CO2 reduction or building a supplier base that in its majority maintains a sustainability program, as well as introducing green energy and circular economy into our processes. For example, we have committed ourselves to 100 % green electricity by 2025,” explained Schneider.

Chemicals providers play a crucial role in the value chain, equipping their customers with the appropriate materials and processes to meet a changing landscape.

“Roquette is currently seeing demand rise again for its pharmaceutical offerings as economies are opening up. For example, from the second half of 2020 through 2021, demand for cold and flu medications was 2% of what it historically is. Now that families are interacting again, demand is coming back.”

Paul Smaltz, VP Global Business Unit Pharmaceuticals, Roquette

Image courtesy of Brenntag

Next:

Interview: Brenntag North America